{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-268942","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.440000+00:00","generated_at":"2026-06-09T00:44:17.602439+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arcellx reports 100% ORR, 76% CR rate in Phase 1 CART-ddBCMA trial; median follow-up 22 mo","bullets":["Overall response rate 100% per IMWG criteria; 29/38 patients (76%) achieved CR or sCR.","Median duration of response, PFS, and OS not reached at 22 months median follow-up.","6-, 12-, 18-month PFS rates by KM: 92%, 74%, 67%. Durable in high-risk subgroups.","All 38 patients triple-refractory; 68% penta-refractory; 89% refractory to last line.","CART-ddBCMA well tolerated; manageable CRS/ICANS, no delayed neurotoxicity or parkinsonism."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-268942","json":"https://secwatch.observer/filing/0001193125-23-268942.json","markdown":"https://secwatch.observer/filing/0001193125-23-268942.md","text":"https://secwatch.observer/filing/0001193125-23-268942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312523268942/0001193125-23-268942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312523268942/d572316d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:44:17.602439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}